glp-1 addiction Weight Loss Drugs May Also Curb Substance Use Disorders Prospects of GLP-1 Therapies for
Description
This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes
Following the predefined inclusion and exclusion criteria, 36 studies were included in this systematic review and underwent qualitative analysis
Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.
Both drugs belong to a family of modern therapies that have changed how clinicians treat diabetes and obesity
